# TG4010 and Nivolumab in Patients With Lung Cancer

> **NCT02823990** · PHASE2 · COMPLETED · sponsor: **Megan Daly, MD** · enrollment: 13 (actual)

## Conditions studied

- Recurrent Non-Small Cell Lung Carcinoma
- Stage I Non-Small Cell Lung Cancer
- Stage II Non-Small Cell Lung Cancer
- Stage IIIA Non-Small Cell Lung Cancer
- Stage IIIB Non-Small Cell Lung Cancer
- Stage IV Non-Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** TG4010
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT02823990
- **Lead sponsor:** Megan Daly, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-14
- **Primary completion:** 2021-02-24
- **Final completion:** 2021-02-24
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-11-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02823990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02823990, "TG4010 and Nivolumab in Patients With Lung Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02823990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*